On November 14, 2022 Apollo Therapeutics (‘Apollo’), a portfolio biopharmaceutical company focusing on translational biology and drug development, and The Institute of Cancer Research, London, a world-leading cancer research organisation, reported they have entered into a strategic collaboration to discover and develop new cancer medicines (Press release, Apollo Therapeutics, NOV 14, 2022, View Source [SID1234624043]). The collaboration combines the strengths and resources of both organisations to bring forward the development of novel therapies for cancer patients worldwide.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As one of the world’s leading cancer research institutions, with more than 800 scientists working across the full spectrum of cancer research, The Institute of Cancer Research (ICR) delivers substantial expertise in cancer biology and drug discovery. Together with its hospital partner The Royal Marsden NHS Foundation Trust, the ICR also brings leading cancer clinical trial experience, including through their joint Drug Development Unit which is the leading oncology-focused Phase I trial unit in the UK.
Apollo’s translational scientists and drug development specialists, who are already developing a diverse portfolio of over 20 therapeutic programs, will work with the ICR on research programs to rapidly and efficiently progress those with the greatest promise through preclinical and clinical development and ultimately to patients globally.
Cancer remains a highly important health challenge, being responsible for around 10m deaths worldwide in 2020 according to the WHO, demonstrating the significant remaining unmet need for effective oncology treatments.*
Dr Richard Mason, Chief Executive Officer of Apollo commented:
"I am delighted to be entering into this collaboration with the ICR, an elite global cancer research organisation. The ICR has a hugely impressive track-record of scientific break-throughs and the discovery of important new medicines which have been approved and are in use globally. I am pleased that Apollo’s strength and experience in drug discovery and development together with our unique collaboration model has attracted an institution with ICR’s credibility and capabilities, allowing us to further deliver on our strategy of capital efficient portfolio drug development, at scale. We look forward to working with the ICR and jointly developing new medicines for cancer patients."
Dr Kristian Helin, Chief Executive Officer of the ICR said:
"It’s a great opportunity for the ICR to be entering this strategic partnership with Apollo. By working together, I hope we can accelerate our ability to translate our scientific discoveries for the benefit for cancer patients. We are looking forward to working with Apollo".
The ICR joins Apollo’s other top global research partners; the University of Cambridge, Imperial College London, UCL and King’s College London.